Clinical Features and Prognosis of Pulmonary Lymphoepithelioma-like Carcinoma: Summary of Eighty-five Cases
| Autor: | Xiaohong Xie, Wei-jie Guan, Xinqing Lin, Rongchang Chen, Zheng Zhu, Nanshan Zhong, Shiyue Li, Guoying Gao, Zhanhong Xie, Chengzhi Zhou, Ouyang Ming, Yinyin Qin |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male 0301 basic medicine Pulmonary and Respiratory Medicine Cancer Research medicine.medical_specialty Lung Neoplasms medicine.medical_treatment Respiratory Mucosa Gastroenterology Young Adult 03 medical and health sciences 0302 clinical medicine Carcinoma Non-Small-Cell Lung Internal medicine Carcinoma Humans Medicine Progression-free survival Lung cancer Neoplasm Staging Univariate analysis Chemotherapy Performance status business.industry Middle Aged Prognosis medicine.disease Survival Analysis Gemcitabine Treatment Outcome 030104 developmental biology Pemetrexed Oncology Chemotherapy Adjuvant 030220 oncology & carcinogenesis Female business Follow-Up Studies medicine.drug |
| Zdroj: | Clinical Lung Cancer. 20:e329-e337 |
| ISSN: | 1525-7304 |
| Popis: | Background Pulmonary lymphoepithelioma-like carcinoma (PLELC) is a rare subtype of lung cancer that is less reported and not well-understood. Materials and Methods We investigated the clinical features of 85 patients with PLELC to determine the prognostic factors. Results PLELC preferentially affected the young (71.8%) and nonsmokers (72.9%), without a significant difference in gender. Most (50.6%) patients were at the early stage with opportunity for operation, and patients at advanced stages mainly received multimodality treatment. The median follow-up duration was 17 months (range, 1-39 months) for the whole group, and the 3-year overall survival rate for patients in the early stage was 100%, whereas the 1-year and 2-year overall survival rate for patients in the advanced stage were 93% and 77%, respectively. The tumor stages (P = .031), distant lymph node metastasis (P = .035) and performance status (P = .008) were associated with progression-free survival in the univariate analysis, whereas performance status was an independent prognostic factor in the multivariate analysis (P = .016). The median progression-free survival in the paclitaxel plus platinum (12 months) group and gemcitabine plus platinum (10 months) group were significantly longer than that in the pemetrexed plus platinum (5 months) group (P = .001). Conclusion PLELC had a better prognosis compared with other types of non–small-cell lung cancer and was sensitive to radiotherapy and chemotherapy. Gemcitabine plus platinum and paclitaxel plus platinum should be used as first-line treatment of PLELC, whereas the second-line treatment, if necessary, was always decided by the managing oncologist. The tumor stages and performance status were predictive in the prognosis of patients with PLELC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect